Medplus Health Services

    MEDPLUS
    Consumer
    ₹600.40
    Price as of 18 Nov 2026, 9:58 pm IST

    Market cap ₹7,193 Cr

    P/E
    34.07
    Day range
    ₹595.30 – ₹608.85
    52-week range
    ₹565.60 – ₹1,022.20
    Volume
    1.51 L
    Open
    ₹608.85
    Prev close
    ₹608.85

    Latest results · Q2 FY27(consolidated)Revenue ₹2,037 Cr+21.3%Profit ₹56 Cr+1.0%Margin 2.8%YoY vs the same quarter last year

    1 red flag to read up on

    • high

      Promoter pledge went up

      74.09% of promoter shares pledged, up from 60.74% · 30 Sept 2026

    From NSE and BSE filings. A flag is a reason to read the filing, not a rating.

    Research profile

    Composite 44 / 100

    Factor percentiles

    Value61
    Quality30
    Momentum19
    Low volatility67

    Derived metrics

    Earn. yield
    2.9%
    Graham no.
    ₹256.92
    vs Graham
    -57.2%
    ROE ÷ P/B
    3.3%
    12-1 mom.
    -20.0%
    Return / vol
    -0.73
    Magic Formula
    #423
    FCF yield
    5.2%

    Percentiles rank this stock against the other tracked stocks and change as they do. Scans describe where figures sit today. Hover a label for its definition. Not investment advice.

    Peer comparison

    All 90 in Consumer
    Largest Consumer companies tracked, with sector medians
    CompanyM-capP/EP/BROEROCEOPMD/ESales YoY
    Titan CompanyTITAN₹4.12 L Cr58.6723.8337.1%21.0%14.0%1.51+10.1%
    Asian PaintsASIANPAINT₹2.47 L Cr51.1411.2321.6%26.0%16.0%0.21+16.9%
    Avenue SupermartsDMART₹2.26 L Cr72.598.6012.9%17.0%7.0%0.16+17.8%
    TrentTRENT₹1.70 L Cr89.7321.7527.7%28.0%18.0%0.30+21.9%
    Lenskart SolutionsLENSKART₹1.27 L Cr162.3313.716.8%8.0%22.0%0.37+35.7%
    The Indian Hotels CompanyINDHOTEL₹1.25 L Cr56.359.2918.6%17.0%28.0%0.25+21.7%
    MeeshoMEESHO₹1.17 L Cr188.6427.61-46.6%-40.0%-6.0%0.01+34.4%
    Medplus Health ServicesMEDPLUS₹7,193 Cr34.073.6011.8%13.0%8.0%0.75+21.3%
    Sector median₹10,665 Cr40.834.8313.0%15.0%12.5%0.27+19.1%

    Sector as classified in the tracked universe; medians use every tracked Consumer company, and P/E only profitable ones. Tinted figures beat the median.

    Latest news

    Updated 11h ago

    Headlines about Medplus Health Services from the last two weeks in the financial press. Stories belong to their publishers; Rajat Finance does not endorse them.

    Key metrics

    P/E (TTM)
    35.2
    Price / Book
    3.49
    ROE (FY26)
    11.8%
    ROCE (latest year)
    13%
    Dividend yield
    0.00%

    Moving averages (NSE)

    20-day
    ₹604.28
    Price below
    50-day
    ₹629.71
    Price below
    200-day
    ₹769.9
    Price below

    Charts & trends

    From company filings. Amounts in ₹ crore.

    Revenue 3Y CAGR
    +14.8%
    Profit 3Y CAGR
    +63.9%
    Revenue YoY (Sep 2026)
    +21.3%
    Profit YoY (Sep 2026)
    +0.0%
    Operating margin
    8.0%
    Net margin
    2.7%

    Revenue, profit & margin - quarterly

    ₹ crore; a loss shows red. Operating margin below, same periods.

    0 Cr1K Cr2K Cr3K Cr
    • Revenue
    • Net profit

    Operating margin

    Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Sep 20260%5%10%

    Who owns the company

    % of equity by quarter, latest Sept 2026

    Dec '24Mar '25Jun '25Sept '25Dec '25Mar '26Jun '26Sept '260%25%50%75%100%
    • Promoter
    • DII
    • Public
    • FII
    • Others

    Cash flows

    Where cash came from and went, by fiscal year (₹ crore)

    Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026-1K Cr-500 Cr0 Cr500 Cr1K Cr
    • Operating
    • Investing
    • Financing
    • Free cash flow

    Return on equity

    Net profit over shareholders' equity, by fiscal year

    FY17FY18FY19FY20FY21FY22FY23FY24FY25FY260%10%20%30%15% screen

    Equity vs debt

    Shareholders' equity against borrowings (₹ crore); the ratio below, same years.

    0 Cr1K Cr2K Cr3K Cr
    • Equity
    • Debt

    Debt to equity

    Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Sep 20260x1x2x

    Financial statements

    ₹ Crore
    Quarterly results, oldest period first, figures in rupees crore
    Line itemDec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026
    Sales1,4411,4901,4891,5761,5611,5101,5431,6791,8061,8641,8802,037
    Expenses1,3501,3851,3951,4521,4291,3731,4121,5301,6481,6951,7461,867
    Operating Profit9210694124133136131149159169133170
    OPM %6%7%6%8%8%9%8%9%9%9%7%8%
    Other Income10109121316151718212021
    Interest242525252627272931333337
    Depreciation575960636264666973767884
    Profit before tax203218485761536973804270
    Tax %31%-5%19%19%19%16%20%19%21%20%21%20%
    Net Profit143414394651425658643356
    EPS in Rs₹1.15₹2.79₹1.20₹3.24₹3.83₹4.29₹3.54₹4.63₹4.82₹5.33₹2.76₹4.67

    From company filings, updated 17 Nov 2026. Consolidated figures where the company reports them. Information only, not investment advice.

    Working-capital cycle

    Debtor Days1

    0 days since Mar 2021

    Inventory Days99

    -14 days since Mar 2021

    Days Payable22

    0 days since Mar 2021

    Cash Conversion Cycle79

    -12 days since Mar 2021

    Working Capital Days49

    +3 days since Mar 2021

    Strengths, risks & growth

    Strengths

    • Company has delivered good profit growth of 28.4% CAGR over last 5 years

    Risks

    • Stock is trading at 3.59 times its book value
    • Though the company is reporting repeated profits, it is not paying out dividend
    • Company has a low return on equity of 8.38% over last 3 years.
    • Promoters have pledged 74.1% of their holding.

    Compounded Sales Growth

    10 Years
    +15%
    5 Years
    +18%
    3 Years
    +15%
    TTM
    +21%

    Compounded Profit Growth

    10 Years
    +37%
    5 Years
    +28%
    3 Years
    +66%
    TTM
    +8%

    Stock Price CAGR

    10 Years
    —
    5 Years
    —
    3 Years
    -9%
    1 Year
    -21%

    Return on Equity

    10 Years
    +8%
    5 Years
    +7%
    3 Years
    +8%
    Last Year
    +12%

    Strengths and risks are a machine-generated checklist, not advice; growth is compounded annually over each period.

    Shareholding pattern

    Percentage of shares held by each category at each quarter end
    HolderDec 2025Mar 2026Jun 2026Sept 2026Change
    Promoter40.29%40.22%40.19%40.20%+0.01 pp
    FII16.83%15.53%14.38%12.58%-1.80 pp
    DII26.58%27.82%29.95%31.89%+1.94 pp
    Public16.27%16.41%15.45%15.31%-0.14 pp
    Others0.04%0.04%0.04%0.04%0.00 pp

    Filed with NSE for Sept 2026: promoters 40.19%, public 59.76%

    Analysts & fund holdings

    100%
    100% recommend buy
    7 analysts cover the stock
    Valuation vs Interactive Media & Services
    P/E34.1 vs 78.6
    Sector P/B5.49
    Beta0.41

    Who holds the shares, quarter by quarter

    Mutual funds 27.40% (+2.88 pp)
    Jun 25
    Sept 25
    Dec 25
    Mar 26
    Jun 26
    Sept 26
    • Promoters40.2%
    • Foreign institutions12.6%
    • Mutual funds27.4%
    • Insurance1.2%
    • Other domestic institutions3.3%
    • Retail9.0%
    • Others6.3%
    Mutual funds holding the most
    Fund% of company% of fund3-month change
    ICICI Pru Healthcare Fund4.11%4.30%+0.50 pp
    Kotak Small Cap Fund2.99%1.16%-0.17 pp
    Nippon India Pharma Fund2.77%2.26%-0.43 pp
    SBI ELSS Tax Saver Fund2.04%0.51%-0.38 pp
    Nippon India Multi Cap Fund1.97%0.28%-0.04 pp

    Scorecard

    Performance
    Low
    Valuation
    High
    Growth
    Avg
    Profitability
    High
    Entry point
    Good
    Red flags
    Avg

    Analyst coverage, holdings and scorecard from market data; not a recommendation by Rajat Finance.

    Risk & trend

    From 292 daily sessions to 18 Nov 2026.

    Computed

    Risk

    Volatility (1Y)
    29.4%
    Downside volatility
    29.8%
    Worst 5% of days
    2.7%
    Average of that tail
    4.1%
    Max drawdown (1Y)
    39.2%
    Below its peak
    37.1%

    Against the market

    Beta vs Nifty 50
    0.51
    Correlation
    0.23
    Relative strength (3M)
    -12.4%
    ATR (14)
    3.2%

    Return

    Return 1M
    -1.9%
    Return 3M
    -8.5%
    Return 6M
    -35.3%
    Return 1Y
    -21.5%
    vs 200-day average
    -22.0%

    Momentum

    RSI (14)
    43.0
    MACD histogram
    2.84
    Stochastic %K
    52.6
    ADX (14)
    16.4
    +DI / −DI
    16.8 / 23.1
    Money flow index
    26.7

    Participation

    Delivery (20d avg)
    53.7%
    vs its 60-day baseline
    -3.4 pts
    Volume vs 20-day
    -0.1σ
    Close vs day's VWAP
    +0.0%
    52-week position
    5 / 100

    These describe what this stock's price has already done. They are not forecasts, signals or recommendations, and a dash means the figure was withheld for want of enough history rather than being zero.

    Financial quality

    From consolidated statements to 30 Sept 2026.

    Computed

    No F-Score: it needs two reporting periods a year apart that carry both an income statement and a balance sheet, and this company's filings do not yet line up that way. The ratios below need only the one period and are unaffected.

    Free cash flow
    ₹373 Cr
    FCF yield
    5.2%
    Cash conversion
    2.26
    Accruals ratio
    -0.070
    Net debt
    ₹1,404 Cr
    Net debt / equity
    0.68
    EV / sales
    1.13
    Capex intensity
    1.8%

    Computed from filed statements, not filed themselves. A dash means an input was absent, and the score counts only the criteria that could actually be tested.

    Insider trades

    Last 12 months, market trades
    Net buying ₹24.5 L
    1 buys · ₹24.5 L
    0 sells · ₹0
    Latest insider trades disclosed to NSE
    PersonTypeSharesValueDisclosed
    Alka Ajit Rangnekar
    Directors Immediate Relative · Off Market
    Buy3,725₹24.5 L1 Sept 2026
    AGILEMED INVESTMENTS PRIVATE LIMITED
    Promoters · Revokation of Pledge
    Pledge released41,71,970₹340 Cr26 Dec 2025

    Disclosures filed with NSE under SEBI (Prohibition of Insider Trading) Regulations. Pledges and releases are not trades and are not counted above.

    Corporate actions

    No dividends, splits or bonuses recorded for this company yet.

    Company announcements

    Corp Action
    Announcement under Regulation 30 (LODR)-Daily Buy Back of equity shares

    Daily Buyback Report

    Corp Action
    Announcement under Regulation 30 (LODR)-Daily Buy Back of equity shares

    Daily Buyback Report

    Corp Action
    Announcement under Regulation 30 (LODR)-Daily Buy Back of equity shares

    Daily Buyback Report

    Company Update
    Communication To Shareholders - Buyback

    Communication to Shareholders- BuyBack

    Company Update
    Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

    Intimation of Schedule of Analyst / Institutional Investor Meeting

    Company Update
    Announcement under Regulation 30 (LODR)-Newspaper Publication

    Newspaper Publication of Public Announcement - Buyback

    Company Update
    Announcement under Regulation 30 (LODR)-Public Announcement-Buyback of Shares

    Submission of Board Resolution and Public Announcement - Buyback.

    Board Meeting
    Board Meeting Outcome for Outcome Of Board Meeting Held On November 06, 2026, Approving The Buyback Of Equity Shares.

    Outcome of Board Meeting held on November 06, 2026, approving the buyback of equity shares.

    Insider Trading / SAST
    Disclosures of reasons for encumbrance by promoter of listed companies under Reg. 31(1) read with Regulation 28(3) of SEBI (SAST) Regulations, 2011.

    The Exchange has received the Disclosures of reasons for encumbrance by promoter of listed companies under Reg. 31(1) read with Regulation 28(3) of SEBI (SAST) Regulations, 2011 on October ....

    Insider Trading / SAST
    Disclosures of reasons for encumbrance by promoter of listed companies under Reg. 31(1) read with Regulation 28(3) of SEBI (SAST) Regulations, 2011.

    The Exchange has received the Disclosures of reasons for encumbrance by promoter of listed companies under Reg. 31(1) read with Regulation 28(3) of SEBI (SAST) Regulations, 2011 on October ....

    Insider Trading / SAST
    Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011.

    The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on October 30, 2026 for Agilemed Investments Pvt Ltd

    Insider Trading / SAST
    Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011.

    The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on October 30, 2026 for Lone Furrow Investments Pvt Ltd

    Insider Trading / SAST
    Closure of Trading Window

    Trading Window Closure Under SEBI (Prohibition of Insider Trading) Regulations, 2015

    Board MeetingPrice-sensitive
    Board Meeting Intimation for Considering Buy-Back Of Equity Shares.

    Medplus Health Services Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 06/11/2026 ,inter alia, to consider and approve Buy-Back of Equity Shares.

    Insider Trading / SAST
    Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011

    The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for ICICI Prudential Mutual Fund

    Filed with BSE (scrip 543427); the last 45 days. Documents open at bseindia.com.

    Documents

    Documents open at BSE or the rating agency that issued them.

    Sourced from the company's NSE XBRL filing dated 28 Oct 2026 (unaudited). View the source filing. Figures are as filed and are not investment advice.

    FAQ

    Medplus Health Services: common questions

    Answered from the figures on this page.

    Medplus Health Services last traded at ₹600.40 (NSE, as of 18 Nov 2026). The last session moved it down 1.39%.

    Medplus Health Services is valued at about ₹7,193 crore (NSE, as of 18 Nov 2026).

    Medplus Health Services trades at a price-to-earnings ratio of 34.07 (NSE, as of 18 Nov 2026). The P/E compares the share price with earnings per share, so it is only comparable between companies in the same industry.

    Medplus Health Services has traded between ₹565.60 and ₹1,022.20 over the past 52 weeks, to 18 Nov 2026. It is currently 8% of the way up that range.

    Medplus Health Services (MEDPLUS) is classified under Consumer on this site's screener.